Principal Investigator
Tali Czarnowicki
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20240613
Clinical Trial Summary
A phase 3 randomized, double-blind, 52-week placebo-controlled multi-center study with a double-blind 52-week extension period with randomized dose up/dose down titration investigating the efficacy, safety, and tolerability of ritlecitinib in adult participants with nonsegmental vitiligo
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other